Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3
4 affiliations
- 1Department of Pharmaceutical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra Amman Jordan
- 2Faculty of Pharmacy, Zarqa University Zarqa 13132 Jordan
- 3Department of Chemistry, Faculty of Science, The University of Jordan Amman Jordan
- 4Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan Amman Jordan
Abstract
FMS-like tyrosine kinase 3 (FLT3) is a validated therapeutic target, but resistance mutations such as D835Y compromise its therapeutic utility by conferring resistance to existing inhibitors and limiting therapeutic options in FLT3-driven cancers, such as Acute Myeloid Leukemia (AML). In order to address this challenge and improve upon the modest activity of known isoindigo scaffolds against wild-type FLT3, this study reports the synthesis and docking of novel isoindigo-based derivatives targeting both wild-type and mutant (D835Y) FLT3. First, a series of 3-(2-oxoindolin-3-ylidene)indolin-2-one derivatives was synthesized through Sandmeyer isatin synthesis followed by Knoevenagel-type aldol condensation. Furthermore, molecular docking analysis indicated that the integration of a 1,3-dioxole moiety improves binding interactions within both the active and inactive kinase pockets and molecular dynamics analysis indicated the stability of the derivatives' virtual complexes. Moreover, in vitro assays identified derivatives 3, 5, 8, and 12 as potent nanomolar inhibitors of either or both FLT3 forms, as derivative 3 was the most potent dual inhibitor, with IC50 values of 243.3 nM against wild-type FLT3 and 121.3 nM against the D835Y mutant, while derivative 8 was the most potent against wild-type FLT3 (IC50 = 180.3 nM). These findings identify the optimized isoindigo scaffold as a promising chemical lead for the development of novel FLT3 inhibitors.
Related
- Multistep synthesis of novel indole–benzimidazole hydrazone hybrids as xanthine oxidase inhibitors: In-Vitro evaluation, molecular docking, MD simulations and DFT studies
- Design, synthesis, and biological evaluation of novel triazolopyrimidine–1,2,3-triazole–acetamide hybrids as potent α-glucosidase inhibitors supported by in silico studies
- Design, click synthesis, and biological evaluation of novel uracil-1,2,3-triazole hybrids as dual EGFR/CDK1 inhibitors: antiproliferative activity, mechanistic insights, and in silico studies
- Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel 1,2,4-Triazole-Functionalized Benzene-Sulfonate Derivatives as Potential Enzyme Inhibitors and Cytotoxicity in HepG2 Cells.
- Development of Novel Furan–Chalcone Derivatives as Targeting Bacterial DNA Gyrase and Topoisomerase IV: Design, Synthesis, and In Silico Studies
BibTeX
@article{abadleh2026synthesis,
title = {{Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3}},
author = {Mohammed Abadleh and Ahmad H. Abdullah and Ahmed Adel and Jalal Zahra and Salim S. Sabri and Ghazi Alodwan and Mutasem O. Taha},
journal = {RSC advances},
year = {2026},
month = nov,
doi = {10.1039/d6ra08346c},
url = {https://europepmc.org/article/PMC/PMC13730539},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3
AU - Mohammed Abadleh
AU - Ahmad H. Abdullah
AU - Ahmed Adel
AU - Jalal Zahra
AU - Salim S. Sabri
AU - Ghazi Alodwan
AU - Mutasem O. Taha
PY - 2026
DA - 2026/11/03
JO - RSC advances
DO - 10.1039/d6ra08346c
UR - https://europepmc.org/article/PMC/PMC13730539
AB - FMS-like tyrosine kinase 3 (FLT3) is a validated therapeutic target, but resistance mutations such as D835Y compromise its therapeutic utility by conferring resistance to existing inhibitors and limiting therapeutic options in FLT3-driven cancers, such as Acute Myeloid Leukemia (AML). In order to address this challenge and improve upon the modest activity of known isoindigo scaffolds against wild-type FLT3, this study reports the synthesis and docking of novel isoindigo-based derivatives targeting both wild-type and mutant (D835Y) FLT3. First, a series of 3-(2-oxoindolin-3-ylidene)indolin-2-one derivatives was synthesized through Sandmeyer isatin synthesis followed by Knoevenagel-type aldol condensation. Furthermore, molecular docking analysis indicated that the integration of a 1,3-dioxole moiety improves binding interactions within both the active and inactive kinase pockets and molecular dynamics analysis indicated the stability of the derivatives' virtual complexes. Moreover, in vitro assays identified derivatives 3, 5, 8, and 12 as potent nanomolar inhibitors of either or both FLT3 forms, as derivative 3 was the most potent dual inhibitor, with IC50 values of 243.3 nM against wild-type FLT3 and 121.3 nM against the D835Y mutant, while derivative 8 was the most potent against wild-type FLT3 (IC50 = 180.3 nM). These findings identify the optimized isoindigo scaffold as a promising chemical lead for the development of novel FLT3 inhibitors.
SN - 2046-2069
ER -